Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology leader advancing RNA medicines through its proprietary PRISM platform. This page provides investors and researchers with timely updates on the company's stereopure oligonucleotide therapies targeting genetic disorders.
Access the latest press releases covering clinical trial progress, regulatory milestones, and scientific advancements. Our curated collection includes updates across WVE's pipeline, including programs for Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and neurological conditions.
Key news categories include:
• Clinical development updates
• Strategic research collaborations
• Regulatory pathway announcements
• Scientific publication highlights
Bookmark this page for direct access to primary source materials about WVE's innovative approach to RNA editing and antisense technologies. Monitor critical developments in precision genetic medicine through verified company communications.
Wave Life Sciences (WVE) has announced positive 48-week data from its Phase 2 FORWARD-53 trial of WVE-N531, a treatment for Duchenne muscular dystrophy (DMD). The trial demonstrated a statistically significant 3.8-second improvement in Time-to-Rise versus natural history, marking the largest effect observed compared to any approved dystrophin restoration therapy.
Key findings include:
- Dystrophin expression stabilized at 7.8% average, with 88% of boys achieving above 5%
- 28.6% reduction in muscle fibrosis between weeks 24-48
- 50% decline in creatine kinase levels
- Significant improvements in muscle health markers
Following FDA feedback, Wave plans to file a New Drug Application in 2026 for accelerated approval. The company also intends to submit multiple clinical trial applications for other exon skipping programs in 2026, targeting a potential >$2.4 billion market opportunity in the United States.
Wave Life Sciences (WVE) reported its Q4 and full year 2024 financial results, highlighting significant progress across its RNA medicine pipeline. The company ended 2024 with $302.1 million in cash, extending runway into 2027.
Key developments include: dosing initiation in the INLIGHT obesity trial with WVE-007 (data expected 2H 2025); ongoing multi-dosing in RestorAATion-2 trial of WVE-006 for AATD at 200mg; and advancement toward FORWARD-53 48-week DMD data in Q1 2025.
Financial highlights for 2024 include: revenue of $108.3 million (compared to $113.3M in 2023), R&D expenses of $159.7 million (up from $130.0M), and G&A expenses of $59.0 million (increased from $51.3M). The company reported a net loss of $97.0 million for the full year 2024.
Wave Life Sciences (Nasdaq: WVE) has announced it will host a live webcast and conference call on Tuesday, March 4, 2025, at 8:30 a.m. ET to review the company's fourth quarter and full year 2024 financial results and provide business updates.
The clinical-stage biotechnology company, which focuses on RNA medicines to transform human health, will make the webcast accessible through the "Investor Events" section of their website at https://ir.wavelifesciences.com/events-publications/events.
Analysts who wish to participate in the Q&A portion can join via an audio conferencing link that will provide dial-in information upon registration. An archived version of the webcast will be available on the company's website following the live event.
Wave Life Sciences (WVE) has initiated the Phase 1 INLIGHT clinical trial for WVE-007, a novel obesity treatment targeting INHBE mRNA. The trial follows CTA approval and represents Wave's first siRNA to enter clinical development. WVE-007 is designed as a long-acting GalNAc-siRNA treatment with potential once- or twice-yearly dosing, aiming to achieve healthy weight loss by reducing fat while preserving muscle mass.
The INLIGHT trial will evaluate safety, tolerability, pharmacokinetics, and biomarkers in adults with overweight or obesity, focusing on body weight, composition, and metabolic health outcomes. The company expects to deliver proof-of-concept clinical data in 2025, aligning with FDA draft guidance on weight reduction therapeutics.
Wave Life Sciences (WVE) announced key milestones for 2025 across its clinical programs and pipeline. The company has submitted CTAs for the Phase 1 INLIGHT clinical trial of WVE-007, targeting obesity through INHBE inhibition, with proof-of-concept data expected in 2025.
Key developments include positive interim results from the FORWARD-53 study of WVE-N531 for DMD, showing 9.0% mean dystrophin expression. The company is advancing WVE-003 for Huntington's disease, with plans for a Phase 2/3 study and IND submission in 2H 2025. Their RNA editing program WVE-006 for AATD demonstrated first-ever clinical proof-of-mechanism, with multidose data expected in 2025.
The company is well-capitalized with runway into 2027 and expects multiple clinical milestones throughout 2025, including regulatory feedback for WVE-N531 in Q1 2025.
Wave Life Sciences (WVE) has submitted its first clinical trial application for WVE-007, a novel obesity treatment using siRNA technology to silence the INHBE gene. The therapy aims to achieve sustainable weight loss through fat burning while maintaining muscle mass, with potential for once or twice-annual dosing. Clinical trials are expected to begin in Q1 2025.
Preclinical studies in mice showed that a single dose of WVE-007 achieved weight loss comparable to semaglutide, and when used in combination, doubled the weight loss effect. The upcoming Phase 1 trial will evaluate safety, tolerability, pharmacokinetics, and biomarkers in adults with overweight or obesity.
Wave Life Sciences (WVE), a clinical-stage biotechnology company specializing in RNA medicines, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Paul Bolno, MD, MBA, will deliver a presentation on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET in San Francisco, CA.
Investors and interested parties can access a live webcast of the presentation through the company's Investor Relations website under the 'Investor Events' section. A replay will be available for a time after the event.
Wave Life Sciences (Nasdaq: WVE) has announced its participation in two major investor conferences this December. Paul Bolno, MD, MBA, President and CEO, will represent the company at both events. The first appearance will be an analyst-led fireside chat at the 7th Annual Evercore HealthCONx Conference on December 3, 2024, at 3:00 p.m. ET. The following day, December 4, he will participate in a Neuromuscular Disorders panel at the Citi 2024 Global Healthcare Conference at 1:00 p.m. ET. Both presentations will be available via webcast on the company's investor relations website, with replays accessible for a time.
Wave Life Sciences (Nasdaq: WVE) has announced its participation in the Jefferies London Healthcare Conference. The company's President and CEO, Paul Bolno, MD, MBA, will engage in an analyst-led fireside chat on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET.
The presentation will be accessible through a live webcast in the 'Investor Events' section of Wave Life Sciences' website. A replay will be available for a time after the event.
Wave Life Sciences reported its Q3 2024 financial results, highlighting several key achievements. The company demonstrated first-ever RNA editing in humans through its WVE-006 trial for alpha-1 antitrypsin deficiency. Cash position stands at $310.9 million as of September 30, 2024, plus additional $28 million from greenshoe option, extending runway into 2027. The company received supportive FDA feedback on WVE-003 for Huntington's disease and reported positive interim data from FORWARD-53 study of WVE-N531. Wave also announced three new GalNAc-AIMer preclinical programs for cardiometabolic diseases and plans to initiate WVE-007 clinical trial for obesity in Q1 2025.
